Immunotherapy News and Research

Latest Immunotherapy News and Research

MD Anderson's James P. Allison to receive 2014 Louisa Gross Horwitz Prize for work on immunotherapy

Columbia University will award the 2014 Louisa Gross Horwitz Prize to James P. Allison, PhD, of the University of Texas MD Anderson Cancer Center, for his work on understanding the process of T-cell activation and for developing therapies that harness the immune system to fight cancer.

3 Oct 2014

Ganymed, BioNTech AG open new headquarters and research facility in Germany

BioNTech AG and Ganymed Pharmaceuticals AG, two premier German biotechology companies, announced today the joint- opening of a new approx. 10,000 square-meters (108,000 square-feet) headquarters and research facility.

1 Oct 2014

Brain cancer patients can benefit from Rapamycin drug

Every day, organ transplant patients around the world take a drug called rapamycin to keep their immune systems from rejecting their new kidneys and hearts.

30 Sep 2014

Individuals can improve asthma symptoms by avoiding air pollution

People who suffer from asthma may think there's not a lot they can do to control their asthma besides properly taking medications and avoiding allergic triggers.

30 Sep 2014

AZD9291 shows median progression-free survival in patients with EGFRm T790M+ advanced NSCLC

Updated data from the ongoing AURA study of AZD9291 shows encouraging, although still immature, median progression free survival of 9.6 months (95% CI 8.3 to NC) in patients with epidermal growth factor receptor mutation positive (EGFRm) T790M+ advanced non-small cell lung cancer (NSCLC) who had disease progression following treatment with an EGFR tyrosine kinase inhibitor (EGFR TKI).

30 Sep 2014

PD-L1 protein could be a potential immunotherapy target for malignant pleural mesothelioma

Treating patients with high-dose radiotherapy after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival, according to data from a prospective randomized phase II trial presented at ESMO 2014 Congress in Madrid.

30 Sep 2014

Nivolumab drug achieves superior response rates in previously-treated advanced melanoma patients

The monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy in patients whose melanoma has progressed after treatment with ipilimumab, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.

30 Sep 2014

NCCN ORP awards four research grants to advance development of nintedanib

The National Comprehensive Cancer Network Oncology Research Program has awarded four grants to investigators to evaluate and define the clinical effectiveness of the investigational compound nintedanib (BIBF 1120) in non-small cell lung, colorectal, and gastrointestinal cancers.

25 Sep 2014

Ohio State researchers develop novel anticancer peptide vaccines and inhibitors

Researchers have developed two new anticancer peptide vaccines and two peptide inhibitors as part of a larger peptide immunotherapy effort at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

25 Sep 2014

XAGE1 antibody confers survival benefits to lung adenocarcinoma patients

Patients with advanced lung adenocarcinoma who produce the XAGE1 antibody appear to survive twice as long as those who do not produce it, Japanese study data show.

24 Sep 2014

ImmunoCellular signs licensing agreement with Caltech to develop antigen-specific T-cell technology

ImmunoCellular Therapeutics, Ltd. announced today that it has established a licensing agreement with the California Institute of Technology for exclusive rights to novel technology for the development of certain antigen specific T-cell immunotherapies for the treatment of cancer.

24 Sep 2014

Inovio, GeneOne to advance DNA-based Ebola vaccine into phase I clinical trial

Inovio Pharmaceuticals, Inc. announced it will advance its DNA vaccine for Ebola into a phase I clinical trial in a collaboration with GeneOne Life Science Inc., an international DNA vaccine manufacturer in which Inovio holds a minority interest.

24 Sep 2014

Amgen seeks FDA approval for leukemia drug blinatumomab

Amgen today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration seeking approval for its investigational bispecific T cell engager (BiTE) antibody construct, blinatumomab.

22 Sep 2014

TxCell to provide update on immunotherapy products at Société Générale Healthcare & Biotechnology Conference

TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that it will participate at the Société Générale Healthcare & Biotechnology Conference.

22 Sep 2014

Longer looks: Lithium in the water; controlling cancer; recovering from brain injury

There are many kinds of cancer, but treatments have typically combatted them in one way only: by attempting to destroy the cancerous cells. Surgery aims to remove the entire growth from the body; chemotherapy drugs are toxic to the cancer cells; radiation generates toxic molecules that break up the cancer cells' DNA and proteins, causing their demise.

19 Sep 2014

LSU Health researchers reveal how Chop plays crucial role to combat cancer

Research led by Paulo Rodriguez, PhD, an assistant research professor of Microbiology, Immunology & Parasitology at LSU Health New Orleans' Stanley S. Scott Cancer Center, has identified the crucial role an inflammatory protein known as Chop plays in the body's ability to fight cancer.

19 Sep 2014

Penn Medicine, Wistar Institute awarded NCI grants for four new melanoma research projects

Penn Medicine and The Wistar Institute have been awarded a prestigious $12.1 million SPORE grant from the National Cancer Institute. The five-year Specialized Programs of Research Excellence, or SPORE, grant will fund four new melanoma research projects that aim to translate fundamental laboratory discoveries into new therapeutics to treat melanoma and other skin cancers.

18 Sep 2014

Leaky intestines may cripple bacteria-fighting immune cells in patients with CVID

Leaky intestines may cripple bacteria-fighting immune cells in patients with a rare hereditary disease, according to a study by researchers in Lausanne, Switzerland. The study, published in The Journal of Experimental Medicine, may explain why these patients suffer from recurrent bacterial infections.

16 Sep 2014

Cancer Research UK, CRT partner with Asterias to trail novel immunotherapy treatment for lung cancer

CANCER RESEARCH UK and Cancer Research Technology , the charity's development and commercialisation arm, have reached an agreement with Asterias Biotherapeutics, Inc., a biotechnology company in the emerging field of regenerative medicine, to take forward Asterias' novel immunotherapy treatment AST-VAC2 into clinical trials in subjects with non-small cell lung cancer.

11 Sep 2014

Merck's Keytruda gets FDA approval for treatment of malignant melanoma

The recent approval of Merck & Co.'s Keytruda by the U.S. Food and Drug Administration for the treatment of malignant melanoma is a significant milestone for Merck & Co. and for the oncology immunotherapy drug market. Decision Resources Group anticipates the launch of Keytruda as the first anti-PD-1 immunotherapy in the United States for treatment of advanced and unresectable malignant melanoma.

10 Sep 2014

Immunotherapy News and Research

Latest Immunotherapy News and Research

MD Anderson's James P. Allison to receive 2014 Louisa Gross Horwitz Prize for work on immunotherapy

Ganymed, BioNTech AG open new headquarters and research facility in Germany

Brain cancer patients can benefit from Rapamycin drug

Individuals can improve asthma symptoms by avoiding air pollution

AZD9291 shows median progression-free survival in patients with EGFRm T790M+ advanced NSCLC

PD-L1 protein could be a potential immunotherapy target for malignant pleural mesothelioma

Nivolumab drug achieves superior response rates in previously-treated advanced melanoma patients

NCCN ORP awards four research grants to advance development of nintedanib

Ohio State researchers develop novel anticancer peptide vaccines and inhibitors

XAGE1 antibody confers survival benefits to lung adenocarcinoma patients

ImmunoCellular signs licensing agreement with Caltech to develop antigen-specific T-cell technology

Inovio, GeneOne to advance DNA-based Ebola vaccine into phase I clinical trial

Amgen seeks FDA approval for leukemia drug blinatumomab

TxCell to provide update on immunotherapy products at Société Générale Healthcare & Biotechnology Conference

Longer looks: Lithium in the water; controlling cancer; recovering from brain injury

LSU Health researchers reveal how Chop plays crucial role to combat cancer

Penn Medicine, Wistar Institute awarded NCI grants for four new melanoma research projects

Leaky intestines may cripple bacteria-fighting immune cells in patients with CVID

Cancer Research UK, CRT partner with Asterias to trail novel immunotherapy treatment for lung cancer

Merck's Keytruda gets FDA approval for treatment of malignant melanoma

eBook: The Ultimate Guide to Successful Immunofluorescence eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Immunotherapy News and Research

Latest Immunotherapy News and Research

eBook: The Ultimate Guide to Successful Immunofluorescence eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in